Susceptibilities of Legionella spp. to newer antimicrobials in vitro

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 6, 1998, Pages 1520-1523

  Schulin T ^a,b   Wennersten, C B ^a   Ferraro, M J ^b,c   Moellering Jr , R C ^a,b   Eliopoulos, G M ^a,b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; DALFOPRISTIN; EPEREZOLID; ERYTHROMYCIN; KETOLIDE; LINEZOLID; MACROLIDE; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINUPRISTIN; RIFAMPICIN; RIFAPENTINE; ROXITHROMYCIN; UNCLASSIFIED DRUG;

ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATION; DRUG ACTIVITY; DRUG POTENCY; DRUG SENSITIVITY; INCUBATION TIME; LEGIONELLA; LEGIONELLA PNEUMOPHILA; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

EID: 0344333460     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.6.1520     Document Type: Article

References (36)

1. Agouridas, C., A. Bonnefoy, K. Braham, P. Collette, M. Guitton, A. Hochet, P. Mauvais, and J. F. Chantot. 1995. RU 004: uptake in phagocytes, intracellular bioactivity and other immunomodulatory effects, abstr. F175, p. 143. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
2. Baltch, A. L., R. P. Smith, and W. Ritz. 1995. Inhibitory and bactericidal activities of levofloxacin, ofloxacin, erythromycin, and rifampin used singly and in combination against Legionella pneumophila. Antimicrob. Agents Chemother. 39:1661-1666.
3. Barker, J., and I. D. Farrell. 1986. The effect of charcoal on MICs for Legionella. J. Antimicrob. Chemother. 17:127.
4. Bornstein, N., C. Roudier, and J. Fleurette. 1985. Determination of the activity on Legionella of eight macrolides and related agents by comparative testing on three media. J. Antimicrob. Chemother. 15:17-22.
5. Bornstein, N., H. Behr, Y. Brum, and J. Fleurette. 1995. In vitro activity of RU 004 on Legionella species, abstr. F166, p. 142. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
6. Chen, S. C. A., M. L. Paul, and G. L. Gilbert. 1993. Susceptibility of Legionella species to antimicrobial agents. Pathology 25:180-183.
7. Collins, L. A., C. B. Wennersten, M. J. Ferraro, R. C. Moellering, Jr., and G. M. Eliopoulos. 1994. Comparative activities of piperacillin and tazobactam against clinical isolates of Legionella spp. Antimicrob. Agents Chemother. 38:144-146.
8. Desnottes, J. F., and N. Diallo. 1992. Cellular uptake and intracellular bactericidal activity of RP 59500 in murine macrophages. J. Antimicrob. Chemother. 30(Suppl. A):107-115.
9. Dournon, E., P. Rajagopalan, J. L. Vilde, and J. J. Pocidalo. 1986. Efficacy of pefloxacin in comparison with erythromycin in the treatment of experimental guinea pig legionellosis. J. Antimicrob. Chemother. 17(Suppl. B):41-48.
10. Dubois, J., and J. R. Joly. 1992. In vitro activity of RP 59500, a new synergistic antibacterial agent, against Legionella spp. J. Antimicrob. Chemother. 30(Suppl. A):77-81.
11. Edelstein, P. H., M. A. C. Edelstein, K. H. Lehr, and J. Ren. 1996. In-vitro activity of levofloxacin against clinical isolates of Legionella spp., its pharmacokinetics in guinea pigs, and use in experimental Legionella pneumophila pneumonia. J. Antimicrob. Chemother. 37:117-126.
12. Edelstein, P. H. 1991. Rifampin resistance of Legionella pneumophila is not increased during therapy for experimental Legionnaires disease: a study of rifampin resistance using a guinea pig model of Legionnaires disease. Antimicrob. Agents Chemother. 35:5-9.
13. Edelstein, P. H. 1993. Legionnaires' disease. Clin. Infect. Dis. 16:741-749.
14. Edelstein, P. H. 1995. Antimicrobial chemotherapy for Legionnaires' disease: a review. Clin. Infect. Dis. 21(Suppl. 3):S265-S276.
15. Edelstein, P. H., and R. D. Meyer. 1980. Susceptibility of Legionella pneumophila to twenty antimicrobial agents. Antimicrob. Agents Chemother. 18: 403-408.
16. Edelstein, P. H., M. A. C. Edelstein, J. Weidenfeld, and M. B. Dorr. 1990. In vitro activity of sparfloxacin (CI-978; AT-4140) for clinical Legionella isolates, pharmacokinetics in guinea pigs, and use to treat guinea pigs with L. pneumophila pneumonia. Antimicrob. Agents Chemother. 34:2122-2127.
17. Eliopoulos, G. M., E. Reiszner, M. J. Ferraro, C. B. Wennersten, and R. C. Moellering, Jr. 1988. Effect of growth medium on activity of fluoroquinolones and other antimicrobial agents against Legionella species. Rev. Infect. Dis. 10(Suppl. 1):S56.
18. Fitzgeorge, R. B., D. H. Gibson, R. Jepras, and A. Baskerville. 1985. Studies on ciprofloxacin therapy of experimental Legionnaires' disease. J. Infect. 10:194-203.
19. Gabler, W. L. 1991. Fluxes and accumulation of tetracyclines by human blood cells. Res. Commun. Chem. Pathol. Pharmacol. 72:39-51.
20. Havlichek, D., L. Saravolatz, and D. Pohlod. 1987. Effect of quinolones and other antimicrobial agents on cell-associated Legionella pneumophila. Antimicrob. Agents Chemother. 31:1529-1534.
21. Herrera-Insúa, I., K. Jacques-Palaz, B. E. Murray, and R. M. Rakita. 1996. Intracellular activities of RP 59500 (quinupristin/dalfopristin) and sparfloxacin against Enterococuss faecium. Antimicrob. Agents Chemother. 40:886-890.
22. Horwitz, M. A., and S. C. Silverstein. 1982. Legionnaire's disease bacterium (Legionella pneumophila) multiplies intracellulary in human monocytes. J. Clin. Invest. 66:441-450.
23. Horwitz, M. A., and S. C. Silverstein. 1983. Intracellular multiplication of Legionnaires' disease bacteria (Legionella pneumophila) in human monocytes is reversely inhibited by erythromycin and rifampin. J. Clin. Invest. 71:15-28.
24. Johnson, D. M., M. E. Erwin, M. S. Barret, B. Brings Gooding, and R. N. Jones. 1992. Antimicrobial activity of ten macrolide, lincosamine and streptogramin drugs tested against Legionella species. Eur. J. Clin. Microbiol. Infect. Dis. 11:751-755.
25. Mason, E. O., Jr., L. B. Lamberth, and S. L. Kaplan. 1996. In vitro activities of oxazolidinones U-100592 and U-100766 against penicillin-resistant and cephalosporin-resistant strains of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 40:1039-1040.
26. Meyer, R. D. 1991. Role of quinolones in the treatment of legionellosis. J. Antimicrob. Chemother. 28:623-625.
27. Nguyen, M. H., J. E. Stout, and V. L. Yu. 1991. Legionellosis. Infect. Dis. Clin. N. Am. 5:561-584.
28. Nowicki, M., J. C. Paucod, N. Bornstein, H. Meugnier, J. Freney, P. Isoard, and J. Fleurette. 1987. Traitement par la doxycycline de la légionellose experimentale du cobaye infecté par aérosole. Pathol. Biol. 35:865-869.
29. Pendland, S. L., S. J. Martin, C. Chen, P. C. Schreckenberger, and L. H. Danziger. 1997. Comparison of charcoal- and starch-based media for testing susceptibilities of Legionella species to macrolides, azalides, and fluoroquinolones. J. Clin. Microbiol. 35:3004-3006.
30. Ruckdeschel, G., and S. Lob. 1996. In vitro activity of a new 8-methoxyquinolone, BAY 12-8039, against Legionella spp. in comparison to ciprofloxacin (CIP), erythromycin (ERY) and rifampin (RIF), abstr. F7, p. 101. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
31. Saito, A., H. Koga, H. Shigeno, K. Watanabe, K. Mori, S. Kohno, Y. Shigeno, Y. Suzuyama, K. Yamaguchi, M. Hirota, et al. 1986. The antimicrobial activity of ciprofloxacin against Legionella species and the treatment of experimental Legionella pneumonia in guinea pigs. J. Antimicrob. Chemother. 10:251-260.
32. Saito, A., K. Sawatari, Y. Fukuda, M. Nagasawa, H. Koga, A. Tomonaga, H. Nakazato, K. Fujita, Y. Shigeno, Y. Suzuyama, K. Yamaguchi, K. Izumikawa, and K. Hara. 1485. Susceptibility of Legionella pneumonia to ofloxacin in vitro and in experimental Legionella pneumonia in guinea pigs. Antimicrob. Agents Chemother. 28:15-20.
33. Schülin, T., C. B. Wennersten, M. J. Ferraro, R. C. Moellering, Jr., and G. M. Eliopoulos. 1997. Susceptibility of Legionella spp. to ketolide HMR 3647 and other newer antimicrobials, abstr. F-250, p. 188. In Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
34. Spangler, S. K., M. R. Jacobs, and P. C. Appelbaum. 1996. Activities of RPR 106972 (a new oral streptogramin), cefditoren (a new oral cephalosporin), two new oxazolidinones (U-100592 and U-100766), and other oral and parental agents against 203 penicillin-susceptible and -resistant pneumococci. Antimicrob. Agents Chemother. 40:481-484.
35. Stout, J. E., and V. L. Yu. 1997. Legionellosis. N. Engl. J. Med. 337:682-687.
36. Zurenko, G. E., B. H. Yagi, R. D. Schaadt, J. W. Allison, S. E. Glickman, D. K. Hutchinson, M. R. Barbachyn, and S. J. Brickner. 1996. In vitro activity of U-100592 and U-100766. novel oxazolidinone antibacterial agents. Antimicrob. Agents Chemother. 40:839-845.